BIRC6 modifies risk of invasive bacterial infection in Kenyan children.

- James J Gilchrist^{1,2,3*}, Silvia Kariuki⁴, James A Watson^{5,6}, Gavin Band³, Sophie
- ⁵ Uyoga⁴, Carolyne M Ndila⁴, Neema Mturi⁴, Salim Mwarumba⁴, Shebe
- ⁶ Mohammed⁴, Moses Mosobo⁴, Kirk A Rockett³, Alexander J Mentzer³, Dominic P
- ⁷ Kwiatkowski^{3,7}, Adrian VS Hill^{3,8}, Kathryn Maitland^{4,9}, J Anthony G Scott^{4,10},
- **Thomas N Williams**^{4,11*}

*For correspondence:

james.gilchrist@paediatrics.ox.ac uk (JJG); twilliams@kemri-wellcome.org (TNW)

¹Department of Paediatrics, University of Oxford, Oxford, UK; ²MRC–Weatherall Institute of Molecular Medicine. University of Oxford. Oxford. UK: ³Wellcome Centre for 10 Human Genetics, University of Oxford, Oxford, UK; ⁴KEMRI-Wellcome Trust Research 11 Programme, Centre for Geographic Medicine Research-Coast, Kilifi 80108, Kenya; 12 ⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 13 University of Oxford, Oxford, UK; ⁶Mahidol Oxford Tropical Medicine Research Unit, 14 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand: ⁷Wellcome Sanger 15 Institute, Cambridge, UK; ⁸The Jenner Institute, University of Oxford, Oxford, UK; 16 ⁹Division of Medicine, Imperial College, London, UK: ¹⁰Department of Infectious 17 Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; 18 ¹¹Institute for Global Health Innovation, Department of Surgery and Cancer, Imperial 19 College, London, UK 20 21

22 Abstract

- ²³ Invasive bacterial disease is a major cause of morbidity and mortality in African children. Despite
- ²⁴ being caused by diverse pathogens, children with sepsis are clinically indistinguishable from one
- ²⁵ another. In spite of this, most genetic susceptibility loci for invasive infection that have been
- discovered to date are pathogen specific and are not therefore suggestive of a shared genetic
- architecture of bacterial sepsis. Here we utilise probabilistic diagnostic models to identify
 children with a high probability of invasive bacterial disease among critically unwell Kenvan
- children with a high probability of invasive bacterial disease among critically unwell Keny.
- ²⁹ children with *P. falciparum* parasitaemia. We construct a joint dataset including 1,445
- ³⁰ bacteraemia cases and 1,143 severe malaria cases, and population controls, among critically
- unwell Kenyan children that have previously been genotyped for human genetic variation. Using
- these data we perform a cross-trait genome-wide association study of invasive bacterial infection,
- ³³ weighting cases according to their probability of bacterial disease. In doing so we identify and
- validate a novel risk locus for invasive infection secondary to multiple bacterial pathogens, that
- has no apparent effect on malaria risk. The locus identified modifies splicing of *BIRC6* in
- stimulated monocytes, implicating regulation of apoptosis and autophagy in the pathogenesis of
 sepsis in Kenyan children.
- 38

39 Introduction

⁴⁰ Invasive bacterial diseases are a major cause of child morbidity and mortality in Africa (*Berkley*

et al., 2005). Although improved control measures, including the rollout of anti-bacterial conju-

42 gate vaccines (Cowgill et al., 2006; Silaba et al., 2019), have led to recent declines, the burden of

- conditions such as pneumonia, meningitis and sepsis secondary to bacterial pathogens remains
 significant (*Vos et al., 2020*). A better understanding of the biology of invasive bacterial infections
- significant (*Vos et al., 2020*). A better understanding of the biology of invasive
 in African populations might help the development of novel interventions.
- ⁴⁵ In African populations might help the development of novel intervention
- Susceptibility to invasive bacterial infections varies widely between individuals. In African children, some of this variability is determined by acquired comorbidities such as HIV, malnutrition and
- malaria (Berklev et al., 2005; Church and Maitland, 2014; Scott et al., 2011). However, the identi-
- ⁴⁹ fication of common genetic variants as determinants of bacterial infection suggests that a signifi-
- ⁵⁰ cant portion of this variability is heritable. Many of these genetic susceptibility loci have pathogen-
- specific effects (Davila et al., 2010; Gilchrist et al., 2018; Rautanen et al., 2016), which is consistent
- ⁵² with our understanding of infection susceptibility derived from primary immunodeficiencies. Key
- examples of pathogen-specificity among primary immunodeficiencies include Mendelian suscep-
- tibility to mycobacterial disease and susceptibility to non-tuberculous mycobacteria and nonty-
- ⁵⁵ phoidal Salmonella (Bustamante et al., 2014), terminal complement deficiencies and meningococ-
- cal disease (*Figueroa et al., 1993*), and IRAK4 deficiency and pneumococcal disease (*Picard et al., 2007*). A major exception to this is the rs334 A>T mutation in *HBR* (sickle haemoglobin), which is as-
- 2007). A major exception to this is the rs334 A>1 mutation in HBB (sickle haemoglobin), which is associated with raised and lowered risks of infection secondary to a broad range of pathogens among
- ⁵⁹ homozygotes (*Williams et al., 2009*) and heterozygotes (*Scott et al., 2011*) respectively. However,
- the effect sizes associated with sickle haemoglobin are extreme, being maintained in populations
- by balancing selection, and larger sample sizes will probably be needed for the discovery of new
- ⁶² variants with multi-pathogen effects.
- Because the clinical features of invasive bacterial infections and severe malaria are broadly similar (*Beion et al.*, 2007). it can be difficult to distinguish between severe illness caused by extensive 64 sequestration of malaria parasites in the microvasculature ('true' severe malaria) and bacterial sep-65 sis in the presence of incidental parasitaemia on the basis of clinical features alone. This is made 66 harder still by the fact that antibiotic pre-treatment and inadequate blood-culture volumes mean 67 that, even in settings with excellent diagnostic facilities, true invasive bacterial infections can often 68 not be confirmed (Driscoll et al., 2017). Recently, we illustrated this clinical complexity through a 69 study in which we used probabilistic models based on malaria-specific biomarkers to show that 70 approximately one third of children recruited to studies in Africa with a clinical diagnosis of severe 71 malaria were actually suffering from other conditions (*Watson et al., 2021a*,b). 72

In the current study, we extend this work to show that invasive bacterial infections are common in children admitted to hospital with a clinical diagnosis of severe malaria, but in whom biomarkers subsequently suggest that malaria was probably not the primary cause for their severe illness. We then construct a dataset of genome-wide genotyped samples from 5,400 Kenyan children, comprising critically unwell Kenyan children with bacteraemia (*Rautanen et al., 2016*) and severe malaria (*Band et al., 2019*), and population controls. Using this dataset we perform a GWAS of invasive bacterial infection in Kenyan children, weighting cases according to the probability that their disease

was mediated by a bacterial pathogen. In doing so, we increase our study power and identify *BIRC6*

as a novel genetic determinant of invasive bacterial disease in Kenyan children.

82 Results

83 Severe malaria probability and risk of bacteraemia

- ⁸⁴ Children admitted to the high dependency ward of Kilifi County Hospital with a clinical diagnosis
- of severe malaria, defined as a severe febrile illness in the presence of *P. falciparum* parasitaemia
- (n=2,200), between 11th June 1995 and 12th June 2008 were included in the study. While this definition is sensitive it is not specific, meaning that our study will have included some children
 - definition is sensitive it is not specific, meaning that our study with have included some children

Model	Numbers	Sex (female)	Age (months)	Bacteraemia	Mortality
	Total (n=1,400)	695 (49.6%)	29 (17-44)	51 (3.6%)	155 (11.1%)
<i>Pf</i> HRP2/Plt	P(SM Data)>0.5 (n=975)	497 (51.0%)	29 (18-45)	23 (2.4%)	94 (7.4%)
	P(SM Data)<0.5 (n=425)	198 (46.6%)	28 (16-43)	28 (6.6%)	61 (14.4%)
	Total (n=2,220)	1,074 (48.4%)	28 (15-43)	78 (3.5%)	256 (11.6%)
WBC/Plt	P(SM Data)>0.5 (n=1,279)	623 (48.7%)	29 (17-44)	32 (2.5%)	106 (8.4%)
	P(SM Data)<0.5 (n=941)	451 (47.9%)	25 (13-40)	46 (4.9%)	150 (15.9%)

Table 1. Demographics & clinical characteristics of Kenyan children with severe malaria.

Mortality reflects in-patient deaths. Figures are absolute numbers with percentages or interquartile ranges in parentheses. P(SM|Data) reflects the probability of 'true' severe malaria estimated from each model (*Pf*HRP2/Platelet count, White blood cell count/Platelet count).

with sepsis accompanied by incidental parasitaemia (Watson et al., 2021a). We therefore used 88 two probabilistic models, which included either platelet counts and plasma *Pf*HRP2 concentrations 89 (Model 1, n=1.400) or white blood cell and platelet counts (Model 2, n=2.200), to determine the 90 likelihood of 'true' severe malaria among these children. The estimated probabilities of 'true' severe 91 malaria using each model were well-correlated (r = 0.64). Of 1.400 children with a clinical diagnosis 92 of severe malaria with measured plasma PfHRP2 concentrations, 425 (30.4%, Figure 1A and 1B) 93 had a low probability (P(SM|Data)<0.5) of having 'true' severe malaria (941 of 2,220 children using 94 WBC and platelet count data. Figure 1-figure supplement 1A and 1B). That is, while they presented 95 with febrile illness and concomitant malaria parasitaemia, it is unlikely that their illnesses were 96 directly attributable to malaria. In keeping with the hypothesis that a significant proportion of these critically unwell children 98 represented culture-negative invasive bacterial disease (Figure 1), in-patient mortality was higher 99 among children with a low than a high probability of 'true' severe malaria (Table 1; $OR_{model1} = 1.57$, 100 95% Cl 1.11 – 2.21, p = 0.01; $OR_{model?} = 2.09$, 95% Cl 1.60 – 2.72, $p = 4.91 \times 10^{-8}$). This was also 101

reflected in the rates of concurrent bacteraemia (Table 1; $OR_{model1} = 2.92$, 95% Cl 1.66 – 5.13, p =102 1.07×10^{-4} ; $OR_{model?} = 2.00, 95\%$ Cl 1.27 - 3.17, p = 0.003). Similarly, the constituents of model 1 103 were each associated with blood culture positivity, both higher platelet counts (OR=2.36, 95% CI 104 1.19-4.70, p = 0.014) and lower *Pf*HRP2 levels (OR=0.52, 95% Cl 0.39-0.70, $p = 9.62 \times 10^{-6}$) both 105 being associated with the risk of coincident bacteraemia (Figure 1C and 1D). Conversely, white 106 blood counts in isolation were not associated with risk of concurrent bacteraemia (Figure 1-figure 107 supplement 1). Plasma PfHRP2 is the single best biomarker for severe malaria (Hendriksen et al., 108 2012). In light of this, and given the greater enrichment for concurrent bacteraemia among children 109 with a low probability of 'true' severe malaria as calculated by Model 1 than Model 2, we used Model 110 1 probabilities in downstream analyses where available (n=1,400) and used Model 2 probabilities 111 for all other cases (n=800). 112

GWAS of invasive bacterial disease in Kenyan children

Children with a clinical diagnosis of severe malaria but a low probability of having 'true' severe 114 malaria, are thus enriched for invasive bacterial disease. Motivated by this observation we per-115 formed a genome-wide association study of invasive bacterial infection in Kenvan children in which 116 we included both children with culture-confirmed bacteraemia and children with a clinical diagno-117 sis of severe malaria. Children admitted to Kilifi County Hospital between 1st August 1998 and 118 30th October 2010 with community-acquired bacteraemia were recruited to the study as well as 119 children from the severe malaria study described above. Control children were recruited from 120 the same population between 1st August 2006 and 30th December 2010 as described in detail 121 previously (Scott et al., 2011).



Figure 1. *Pf*HRP2 and platelet count as predictors of severe malaria. (A) Distribution of *Pf*HRP2 concentrations and platelet count among Kenyan children (n=1,400) with a clinical diagnosis of severe malaria. Points are coloured according to the probability of 'true' severe malaria given the data. (B) Distribution of 'true' severe malaria probabilities estimated from platelet count and plasma *Pf*HRP2 concentrations. (C) Platelets counts in children with a clinical diagnosis of severe malaria with and without concomitant bacteraemia. (D) *Pf*HRP2 concentrations in children with a clinical diagnosis of severe malaria with and without concomitant bacteraemia.

Figure 1-Figure supplement 1. White blood cell and platelet count as predictors of severe malaria. (A) Distribution of white blood cell and platelet count among Kenyan children (n=2,200) with a clinical diagnosis of severe malaria. Points are coloured according to the probability of 'true' severe malaria given the data. (B) Distribution of 'true' severe malaria probabilities estimated from platelet count and white blood cell count. (C) Platelets counts in children with a clinical diagnosis of severe malaria with and without concomitant bacteraemia. (D) White blood cell counts in children with a clinical diagnosis of severe malaria with and without concomitant bacteraemia.

		Numbers	Sex (female)	Age (months)	Genotyping platform
	Overall	1,445	614 (42.5%)	14 (5-34)	
	Acinetobacter	118	45 (38.1%)	13 (3-28)	
	β-haemolytic Strep.	130	60 (46.2%)	5 (1-20)	
	E. coli	141	58 (41.1%)	11 (6-25)	
Bacteraemia	Hib	113	53 (46.9%)	12 (5-25)	Affy SNP 6.0
	NTS	159	75 (47.2%)	15 (9-26)	
	S. pneumoniae	390	151 (38.7%)	23 (9-61)	
	S. aureus	152	64 (42.1%)	26 (9-88)	
	Other	242	110 (45.5%)	10 (1-28)	
	Overall	1,143	559 (48.9%)	27 (16-41)	
Severe Malaria	P(SM Data)<0.5	375	176 (46.9%)	28 (17-42)	Omni 2.5M
	P(SM Data)>0.5	768	383 (49.9%)	26 (15-40)	
Controls		2,812	1,406 (50%)	*	1,895 Affy SNP 6.0 917 Omni 2.5M

Table 2. Demographics & clinical characteristics of GWAS study samples.

P(SM|Data) reflects the probability of 'true' severe malaria estimated from *Pf*HRP2 concentration and platelet count or white blood cell count and platelet count.

*Control children were recruited between 3 and 12 months of age and have been subject to longitudinal follow-up.

Following guality control measures (see Materials and Methods), we included 1,445 cases of 123 culture-confirmed bacteraemia, 1,143 cases of severe malaria and 2,812 control children in our cur-124 rent analysis (Table 2). To account for the varying proportion of invasive bacterial disease among 125 severe malaria cases, we applied weights to our regression analysis to reflect the greater likelihood 126 of invasive bacterial disease among children with a low probability of 'true' severe malaria (sam-127 ple weight, w = 1 - P(SM|Data)). Where PfHRP2 concentrations were available (n=909) we used 128 PfHRP2 and platelet count to determine P(SM|Data) while we used white cell and platelet counts 129 (n=234) in cases where they were not available. Cases with culture-proven bacteraemia and control 130 samples were assigned a sample weight of w = 1. Inclusion of the 6 major principal components 131 of genotyping data and genotyping platform as covariates in the model adequately controlled for 132 confounding variation ($\lambda = 1.0208$, Figure 2-figure supplement 1). In that analysis we found evi-133 dence supporting an association between risk of invasive bacterial disease in Kenvan children and 134 7 SNPs at a single locus on chromosome 2 (peak SNP: rs183868412:T, OR=2.13, 95% CI 1.65-2.74, 135 $p = 4.64 \times 10^{-9}$) (Figure 2, Table 3). Fine-mapping of this association identified a credible set of 7 136 SNPs with a 95% probability of containing the causal variant (Table 3), spanning a 212kb region: 137 chr2:32.402.640-32.614.746. 138 We sought to replicate evidence of association in our discovery analysis through use of an inde-139

pendent case-control collection of Kenvan children with bacteraemia (n=434) and healthy controls 140 (n=1.258) conducted in the same population. The peak trait-associated variants in the discovery 141 analysis were well-imputed in the replication data (rs183868412 imputation info score = 0.84). In 142 that analysis, we found evidence supporting the association at chromosome 2 with invasive bacte-143 rial disease (Figure 3, Table 4: rs183868412:T, OR=2.77, 95% Cl 1.49-5.12, $p = 1.29 \times 10^{-3}$). In a fixed 144 effects meta-analysis, rs183868412:T was strongly associated with risk of invasive bacterial disease 145 in Kenyan children: OR=2.21, 95% Cl 1.75-2.79, $p = 2.42 \times 10^{-11}$. That association was driven by chil-146 dren with culture-confirmed bacteraemia and critically unwell children with malaria parasites, but 147 a low probability of 'true' severe malaria. In a stratified analysis (Figure 3, Table 4), rs183868412 1/18

SNP	Effect allele	Chr	BP	MAF	Info score	OR (95% CI)	p-value
rs183868412	Т	2	32,478,169	0.021	0.956	2.13 (1.65-2.74)	4.64×10^{-9}
rs139827594	G	2	32,402,640	0.020	0.966	2.12 (1.65-2.73)	4.96×10^{-9}
rs144257579	G	2	32,507,619	0.021	0.954	2.11 (1.64-2.72)	6.82×10^{-9}
rs145056232	С	2	32,503,024	0.021	0.955	2.11 (1.64-2.72)	6.86×10^{-9}
rs145315025	G	2	32,502,654	0.021	0.955	2.11 (1.64-2.72)	6.87×10^{-9}
rs143909151	Т	2	32,531,452	0.021	0.962	2.11 (1.64-2.71)	8.01×10^{-9}
rs150430979	Т	2	32,614,746	0.021	0.955	2.11 (1.64-2.72)	8.18×10^{-9}

Table 3. 95% credible SNP set of invasive bacterial disease association.

MAF, minor allele frequency. CI, confidence interval. Genomic coordinates are GRCh38.

Table 4. Effect of rs183868412 genotype on risk of invasive bacterial disease in Kenyan children.

			Numbers	Genotypes	MAF	OR (95% CI)	p-value
Discovery	Cases	Overall	2,588	3/164/2,421	0.033	2.13 (1.65-2.74)	$p = 4.64 \times 10^{-9}$
		Bacteraemia*	1,445	3/125/1,317	0.045	2.12 (1.60-2.82)	$p=1.94\times 10^{-7}$
		SM - P(SM Data)<0.5*	375	0/20/355	0.027	2.37 (1.27-4.43)	$p=6.82\times 10^{-3}$
		SM - P(SM Data)>0.5*	768	0/19/749	0.012	1.07 (0.57-2.01)	p = 0.823
	Controls		2,812	0/111/2,701	0.020		
Replication	Cases		434	0/24/410	0.028	2.77 (1.49-5.12)	$p = 1.29 \times 10^{-3}$
	Controls		1,258	0/28/1,230	0.011		
Meta-analysis	Cases		3,022	3/188/2,831	0.032	2.21 (1.75-2.79)	$p = 2.42 \times 10^{-11}$
	Controls		4,070	0/139/3,931	0.017		

*estimates derived from multinomial logistic regression model. P(SM|Data) represent the probability of 'true' severe malaria estimated from plasma *Pf*HRP2 concentration and platelet count (n=909) or white blood cell count and platelet count (n=234). SM, severe malaria. MAF, minor allele frequency. CI, confidence interval.

- was associated with culture-confirmed bacteraemia (OR=2.12, 95% Cl 1.60-2.82, $p = 1.94 \times 10^{-7}$) and
- critical illness with parasitaemia and with a low probability of 'true' severe malaria (P(SM | Data)<0.5:
- OR=2.37, 95% CI 1.27-4.43, $p = 6.82 \times 10^{-3}$), but was not associated with risk of critical illness with a
- high probability of 'true' severe malaria (P(SM | Data)>0.5: p = 0.823).

153 The genetic variants associated with invasive bacterial disease in Kenyan children are monomor-

- phic in non-African populations (https://gnomad.broadinstitute.org). Within Africa, rs183868412:T is
- present in all 9 African populations included in the MalariaGEN consortium project (Band et al.,
- **2019**) (Table 5), minor allele frequencies ranging from 0.011 in The Gambia to 0.034 in Malawi.
- There is no evidence for within-Africa differentiation at rs183868412 (p = 0.601).

rs183868412 is associated with risk of invasive bacterial disease secondary to diverse pathogens and is independent of malaria.

Previous data describing the genetic risk of invasive bacterial disease in this population have identified pathogen-specific effects. To better-understand the range of pathogens to which genetic variation at *BIRC6* modifies risk we estimated the effect of rs183868412 on the risk of bacteraemia caused by the seven most common causative pathogens within this population (Figure 4A). In that analysis, the data best-supported a model in which genotype increases risk of bacteraemia caused by a broad range of pathogens, including bacteraemia secondary to pneumococcus, nontyphoidal *Salmonellae*, *E. coli*, β -haemolytic *Streptococci*, *S. aureus* and other less common pathogens grouped

as a single stratum (log10 Bayes factor= 4.72). Genotype at rs183868412 similarly modified risk of



Figure 2. Manhattan plot of invasive bacterial infection in Kenyan children. Evidence for association with invasive bacterial disease at genotyped and imputed autosomal SNPs and indels (n=14,010,600) in Kenyan children (bacteraemia cases = 1,445, severe malaria cases = 1,143, controls = 2,812). Association statistics represent additive association. The red, dashed line denotes $p = 5 \times 10^{-8}$.

Figure 2-Figure supplement 1. Genotyping concordance between Illumina and Affymetrix platforms. Pairwise genotyping concordance between samples genotyped on both Affymetrix SNP 6.0 and Illumina Omni 2.5M platforms.

Figure 2-Figure supplement 2. Principal components of genome-wide genotyping data in discovery samples. Individuals are color-coded according to genotyping platform; Affymetrix SNP 6.0 in purple, Illumina Omni 2.5M in orange.

Figure 2-Figure supplement 3. Principal components of genome-wide genotyping data in discovery samples. Individuals are color-coded according to self-reported ethnicity; Chonyi in red, Giriama in blue, Kauma in green and other in grey.

Figure 2-Figure supplement 4. Quantile-quantile plot of invasive bacterial infection in Kenyan children. QQ plot of weighted logistic regression GWAS of invasive bacterial disease in Kenyan children (2,588 cases, 2,812 controls).

¹⁶⁸ bacteraemia in the neonatal period and in older children (log10 Bayes factor= 2.70, Figure 4B).

Malaria infection results in increased risk of invasive bacterial disease secondary to a broad 169 range of pathogens (Scott et al., 2011), and genetic determinants of malaria risk (e.g. sickle cell 170 trait) modify risk of bacterial infection in malaria-endemic settings (Scott et al., 2011). The ob-17 servation that, among children with a clinical diagnosis of severe malaria, risk of disease is only 172 modified by rs183868412 in children with a low probability that their disease represents 'true' se-173 vere malaria (Figure 3) suggests that the effect of genetic variation at BIRC6 on invasive bacterial 174 disease risk operates independently of malaria. In keeping with this, the data best-supports an ef-175 fect of rs183868412 genotype on bacteraemia risk in children both with and without concomitant 176 parasitaemia (log10 Bayes factor= 2.73, Figure 4C). In addition, unlike sickle cell trait (Scott et al., 177

2011), the increased risk of invasive bacterial infection conferred by rs183868412:T carriage in the

 Table 5. rs183868412 frequencies in Africa.

Population	Number	MAF	
Gambia	2,605	0.011	
Mali	183	0.021	
Burkina Faso	596	0.009	
Ghana	320	0.014	
Nigeria	22	0.024	
Cameroon	685	0.031	
Malawi	1,317	0.034	
Tanzania	402	0.028	
Kenya	1,681	0.017	

Numbers reflect healthy control samples. MAF, minor allele frequency.



Figure 3. Association with invasive bacterial disease at the *BIRC6* locus. (A) Regional association plot of invasive bacterial disease association at the *BIRC6* locus in the discovery and replication analyses. SNPs are coloured according to linkage disequilibrium to rs183868412. Genomic coordinates are GRCh38. (B) Distribution of 'true' severe malaria probabilities among malaria cases estimated from plasma *Pf* HRP2 concentration and platelet count (n=909) and white blood cell count and platelet count (n=234). (C) Odds ratios and 95% confidence intervals of rs183868412 association with disease stratified by malaria cases with high (P>0.5, red) and low (P<0.5, orange) probabilities of 'true' severe malaria and culture-proven invasive bacterial disease (blue). P(SM | Data) represents the probability of 'true' severe malaria estimated from plasma PfHRP2 concentration and platelet count (n=234).

Figure 3–Figure supplement 1. Principal components of genome-wide genotyping data in replication samples. Individuals are color-coded according to self-reported ethnicity; Chonyi in red, Giriama in blue, Kauma in green and other in grey.



Figure 4. Genetic variation at *BIRC6* confers broad susceptibility to invasive bacterial disease. Odds ratios and 95% confidence intervals of rs183868412 association with invasive bacterial disease stratified by pathogen (A), neonatal and non-neonatal sepsis (B) and bacteraemia with and without malaria parasitaemia (C). Odds ratios and 95% confidence intervals of rs183868412 association with invasive bacterial disease stratified by year (D), compared to age-standardized, annual malaria parasite prevalence in Kilifi, Kenya, as estimated from parasite prevalence among trauma admissions (E). We compared models of association across strata using a Bayesian approach (see Methods). Strata associated with rs183868412 genotype in the most likely model in each analysis are highlighted in blue.

study setting is stable across a period of declining malaria prevalence (Bayes factor= 8.7, Figure
 4D).

rs183868412 is associated with alternative splicing of *BIRC6* in stimulated mono-

182 **Cytes**

Trait associated genetic variation identified by GWAS is highly enriched for regulatory variation. The 183 African specificity of the trait-associated variation identified here makes annotation with publicly-184 available regulatory mapping data challenging. To investigate the regulatory function of rs183868412 185 in immune cells in African populations we used eOTL mapping data from 200 (100 European and 186 100 African ancestry) individuals in primary monocytes with and without innate stimulation (Quach 187 et al., 2016); influenza A virus, LPS, Pam3CSK4 (synthetic lipoprotein and TLR1/2 agonist) and R848 188 (a TLR7/8 agonist). In this dataset, we found no evidence for a regulatory effect of rs183868412 189 at the gene level in monocytes regardless of stimulation. We did, however, observe an effect of 190 rs183868412 genotype on expression of a 12bp *BIRC6* exonic sequence (chr2:32,453,943-32,453,954 191 $p = 4.40 \times 10^{-5}$, with evidence for co-localisation of this eOTI with our GWAS signal (posterior 192 probability of colocalisation, PP4 = 0.937, Figure 5). This effect was only observed following stim-193 ulation with Pam3CSK4 (Figure 5), with the bacteraemia risk allele, rs183868412:T, being associ-194 ated with reduced expression of this sequence. That 12bp sequence is associated with an alter-195 native splicing event that results in extension of a *BIRC6* exon. The 23rd exon (ENSE00001189810. 196 chr2:32.453.808-32.453.942) of the canonical *BIRC6* transcript, ENST00000421745.6, is 135bp long 197 and terminates immediately before the 12bp sequence associated with rs183868412:T genotype. 198 The 22nd exon (ENSE00003835010, chr2:32,453,808-32,453,942) of an alternative *BIRC6* transcript. 190 ENST00000648282.1, is 147bp long, having the same start site but including the 12bp sequence 200 at its 3' end. Thus, increased risk of invasive bacterial disease may be associated with decreased 201 expression of an alternative BIRC6 transcript in TLR1/2 stimulated monocytes. 202

203 Discussion

In this study, we have leveraged the close relationship between P falcingrum infection and bacteraemia in African children (Scott et al., 2011) to perform a GWAS of invasive bacterial infection in 205 5,400 Kenvan children. We approached this by defining the probability with which each critically 206 unwell child with a clinical diagnosis of severe malaria has a disease process directly mediated by 207 malaria, that is 'true' severe malaria. We hypothesised that critically unwell children, with a low 208 probability of having 'true' severe malaria, are enriched for invasive bacterial infections. We ex-200 plored the validity of this approach, demonstrating that children with a low probability of 'true' 210 severe malaria were indeed enriched for culture-proven bacteraemia and were at a higher risk of 211 death than children with a higher probability. We therefore performed a GWAS weighting cases 212 according to their likelihood of invasive bacterial disease. In doing so, we have identified and vali-213 dated BIRC6 as a novel genetic susceptibility locus for all-cause invasive bacterial disease in Kenvan 214 children. 215

The disease-associated locus modifies risk of invasive bacterial disease caused by a broad range pathogens, including β -haemolytic *Streptococci*, *E. coli*, nontyphoidal *Salmonella*, *S. pneumoniae* and *S. aureus*. Moreover it modifies risk of invasive infection in both the neonatal period and in older children. Furthermore, in contrast to the rs334 *HBB* A>T mutation (*Scott et al., 2011*), rs183868412 modifies risk of invasive bacterial disease in a manner independent of malaria, with rs183868412:T carriage increasing risk of disease across a period of falling malaria transmission and in children with and without concurrent parasitaemia.

We further demonstrate that rs183868412 mediates risk of invasive bacterial disease through the modification of *BIRC6* splicing in Pam3CSK4-stimulated monocytes. *BIRC6* (Baculovirus inhibitor of apoptosis protein repeat containing 6), also known as *BRUCE* (BIR repeat containing ubiquitinconjugating enzyme), encodes a large member of the inhibitor of apoptosis protein (IAP) family





(Hauser et al., 1998). Members of the IAP family bind to cognate caspases, inhibiting their activity, 227 and thereby cell death, through occlusion of their active site (Verhagen et al., 2001). A proportion 228 of IAPs also contain an E3 ubiguitin ligase allowing both direct inhibition of caspases and targeting 229 of caspases for proteasomal degradation (Verhagen et al., 2001). BIRC6 contains both inhibitor of 230 apoptosis domains and an E2/E3 ubiguitin ligase, which function to inhibit apoptosis in response 231 to a variety of stimuli, both by interaction with and degradation of caspase-9, but also through the 232 ubiguitination and degradation of SMAC, an IAP antagonist (Hao et al., 2004; Bartke et al., 2004). 233 BIRC6 also regulates autophagosome-lysosome fusion (Ebner et al., 2018), and ubiquitinates (and 234 targets for degradation) LC3, a key effector of autophagosome formation. Thus, BIRC6 also acts as 235 a negative regulator of autophagy (Jia and Bonifacino, 2019). 236

It is highly plausible that BIRC6 could determine susceptibility to invasive infection through ei-237 ther its regulation of apoptosis or autophagy (or both). Sepsis induces marked changes in apopto-238 sis across a range of immune cells (Hotchkiss and Nicholson, 2006). There is markedly enhanced 239 apoptosis in both dendritic cells (Hotchkiss et al., 2002) and in lymphocytes. Enhanced lymphocyte 240 apoptosis is most striking in B cells and CD4⁺ T cells (Hotchkiss et al., 2001) which, at least in part. 241 is mediated by caspase-9. The consequent lymphopoenia is correlated with both severity of sep-242 sis and outcome (Le Tulzo et al., 2002). In addition to the direct effects of immune cell loss on the 243 innate and adaptive immune responses to invasive infection, sepsis-induced apoptosis induces im-244 mune cell dysfunction, phagocytosis of apoptotic cells resulting in reduction in pro-inflammatory 245 cytokine production and cross-presentation of antigen from apoptotic cells to adaptive immune 246 cells (Albert, 2004). In keeping with a role for regulators of apoptosis in the pathogenesis of sepsis. 247 members of the IAP family, including NAIP/BIRC1 and BIRC3, are downregulated in immune cells 248 in patients with sepsis, as is the BIRC6 ubiquitination target SMAC (Hoogerwerf et al., 2010). Au-249 tophagy contributes to the direct removal of intracellular pathogens and, through the degradation 250

of invading organisms in autophagosomes, directs antigen presentation and pro-inflammatory cy-

tokine secretion (*Deretic et al., 2013*). As above, *BIRC6* regulates autophagy through its interaction

with LC3, and overexpression of *LC3B* limits inflammation and tissue injury in a mouse model of

254 sepsis (*Lo et al., 2013*).

In keeping with a role for *BIRC6* in autophagy and apoptosis in sepsis, our data identify a role 255 for genetic variation at BIRC6 in determining risk of invasive infection secondary to a broad range of bacteria. This is in contrast to previously-published data describing susceptibility to invasive 257 bacterial infection, which has highlighted a prominent role for genetic risk factors that are spe-258 cific to single pathogens (Davila et al., 2010; Gilchrist et al., 2018; Rautanen et al., 2016). In this 250 study, the derived allele (T) at rs183868412 was associated with increased risk of bacteraemia sec-260 ondary to gram positive (β -haemolytic Streptococci. S. pneumonige and S. gureus) and gram nega-261 tive (E. coli, nontyphoidal Salmonella) pathogens, including intracellular and extracellular bacteria. 262 and enteric and respiratory pathogens. Moreover, rs183868412 modified risk of bacteraemia in 263 both the neonatal period, when infection is likely to be maternally derived, and in older children, 264 when sources of community acquired infection will be more diverse. This modulation of invasive 265 bacterial disease risk, despite diverse sources and routes of infection and diverse mechanisms of 266 invasion, suggests a mechanism in which genetic variation at *BIRC6* modifies risk of invasive infec-267 tion downstream of initial mechanisms of infection and invasion. The African-specific nature of the 268 trait-associated variation identified here limits our ability to comprehensively interrogate the effect 269 of that variation in immune cells. The eOTI mapping data that we utilise here (**Ougch et al., 2016**) is 270 limited in that it allows us only to consider a single immune cell type. A more complete understand-271 ing of the role played by genetic variation at *BIRC6* plays in the pathogenesis of sepsis in African 272 children will require more detailed expression and functional studies in African populations. 273 Taken together, our data identify a role for *BIRC6* in the pathogenesis of invasive bacterial in-274

fections in Kenyan children. By maximising our available sample size to include children with a high likelihood of invasive bacterial infection, but without culture-confirmed infection, we facilitate novel variant discovery and reveal a common genetic architecture of invasive bacterial disease secondary to diverse pathogens. In doing so we expand our understanding of the biology of invasive infection in African children. In particular, these data inform our understanding of the biology shared by diverse bacterial infections causing a common clinical syndrome: sepsis.

281 Materials and Methods

282 Study samples

Recruitment of the severe malaria cases, bacteraemia cases and healthy controls have been de-283 scribed in detail elsewhere (Ndila et al., 2018: Rautanen et al., 2016). In brief, children under 14 284 vears admitted to the high dependency ward of Kilifi County Hospital with a clinical diagnosis of 285 severe malaria, defined as P. falciparum parasites on blood film and at least one of; reduced Blan-286 tyre Coma Score, severe anaemia (Hb<50g/L), evidence of respiratory distress, hypoglycaemia or 287 hyperparasitaemia were eligible for recruitment as cases of severe malaria. During the study pe-288 riod, all children admitted to hospital, with the exception of elective surgical admissions and minor trauma, had a blood sample taken for bacterial culture (BACTEC 9050 instrument, Becton Dickin-290 son, USA). Children under 14 years, in whom a pathogenic organism was identified in blood were 291 eligible for study inclusion (*Bacillus* species, coryneform bacteria, coagulase-negative Staphyococci 292 Staphylococcus saprophyticus and Viridans group Streptococci were considered contaminants). Con-293 trol children were recruited between 3 and 12 months of age from consecutive live births from the 294 population which Kilifi County Hospital serves. Control children have been subject to longitudinal 205 follow-up. 296

²⁹⁷ Models to define the probability of 'true' severe malaria.

Among cases of severe malaria recruited to the study, we used probabilistic models to assign a 298 probability of that child's clinical presentation being mediated by parasite sequestration, that is 299 'true' severe malaria, as described previously (*Watson et al., 2021a*,b). Where available (n=1,400). 300 we used platelet counts and *Pf*HRP2 concentrations to derive the probabilistic model. In cases 301 where PfHRP2 concentration was not measured (n=800), we used white blood cell counts and 302 platelet counts as input data to the model. 303 For both models (Model 1: PfHRP2/platelet counts; Model 2: platelet counts/white blood cell 304 counts), the probabilities of 'true' severe malaria were derived by fitting parametric latent class 305 models. These assumed that each patient had a binary latent state (true severe malaria versus not 306

307 severe malaria). For the Model 1, we assumed that in each latent state the data were distributed as
 308 a single bivariate normal distribution. For the model 2, the data did not fit well to a two-component

⁻ bivariate normal (white blood cell counts have much weaker diagnostic value) so we assumed that

the data had bivariate student-t distribution for the severe malaria state, and a flexible mixture of

³¹¹ bivariates for the not severe malaria state.

Genotyping & imputation

For the discovery analysis, we utilised genotypes generated as part of genome-wide association 313 studies of severe malaria (Band et al., 2019) and bacteraemia (Rautanen et al., 2016) previously 314 reported in this population. Bacteraemia cases and controls were genotyped using the Affymetrix 315 SNP 6.0 array and the severe malaria samples using the Illumina Omni 2.5 M platform, SNP and 316 sample quality control for both datasets are highly analogous, and have been described previously 317 (Band et al., 2019: Rautanen et al., 2016). In brief, MalariaGEN SNP OC excluded poorly geno-318 typed SNPs using the following metrics; SNP missingness >2.5%, minor allele frequency (MAF) <1%, 319 Hardy-Weinberg equilibrium (HWE) $p < 1 \times 10^{-20}$, plate effect $p < 1 \times 10^{-3}$ and a recall test quantify-320 ing changes in genotype following a re-clustering process $p < 1 \times 10^{-6}$. For Affymetrix-genotyped 321 samples, SNP OC excluded SNPs outside the following OC thresholds; SNP missingness >2%, MAF 322 <1%, genotype probability (info) >0.975, plate effect $p < 1 \times 10^{-6}$, and HWE $p < 1 \times 10^{-20}$. Sam-323 ple OC on both platforms excluded sample outliers with respect to channel intensity, missingness. 324 heterozygosity, population outliers and duplicated samples (IBD>0.75). In addition, for Affymetrix-325 genotyped samples, samples were excluded in cases of discordant sex as recorded in the clinical 326 record and imputed from mean intensities from X and Y chromosome markers. 327

To facilitate combining datasets we applied an additional set of cross-platform OC procedures. 328 We defined a shared subset of SNPs genotyped and passing SNP OC on both platforms (n=167.108). 329 observing high levels of genotype concordance (median concordance 0.993, Figure 2-figure sup-330 plement 1) among the subset of samples genotyped on both platforms (n=1.365). We used this 331 shared SNP set to compute relatedness estimates and PCs in PLINK v1.90 (*Chang et al.*, 2015). The 332 major six PCs of shared genotypes differentiate self-reported ethnicity (Figure 2-figure supplement 333 2) and are non-differential with respect to genotyping platform (Figure 2-figure supplement 3). To 334 harmonise OC across both platforms we excluded MalariaGEN samples with discordant clinical 335 and genetic sex (n=136). We further excluded one of duplicate or related sample pairs (IBD>0.2) 336 across platforms, retaining case samples where possible and excluding equal numbers of control samples genotyped on each platform (n=1.973). Following QC, genotypes were phased using 338 SHAPEIT2 (Delaneau et al., 2012), and untyped genotypes imputed genome-wide using IMPUTE2 339 (v2.3.2) (Howie et al., 2011, 2009) with 1000 Genomes Phase III as a reference panel. Following 340 imputation, we excluded SNPs with imputation info scores <0.5. MAF <1% and HWE $p < 1 \times 10^{-5}$. 3/1 applying each threshold for each platform and overall. Following SNP and sample OC, 14.010.600 342 autosomal SNPs and indels from 5,400 samples (1,445 bacteraemia cases, 1,143 severe malaria 343 cases and 2.812 control samples: 917 Illumina genotyped and 1.895 Affymetrix genotyped) were 344 taken forward as a combined discovery dataset for association analysis. 345

Association analysis & fine mapping

346 In the discovery analysis, we tested for association between genotype at each variant passing OC 347 and invasive bacterial disease by logistic regression in an additive linear model. We used weighted 348 logistic regression to reflect the probability of each case sample being a 'true' case of invasive bac-349 terial infection. Cases of culture-confirmed bacteraemia we assigned a weight of 1, whereas cases 350 of severe malaria were assigned weights 1-P(SMIData), re-weighting the contribution of a case to 351 the log-likelihood according to its probability of representing invasive bacterial infection. Control 352 samples were assigned a weight of 1. Our regression thus assumes that the lower the probability 353 of 'true' severe malaria, the greater the probability that a case represents culture-negative invasive 354 bacterial disease. To control for confounding variation, we included the 6 major PCs of genotyping 355 data and genotyping platform as covariates in the model. Weighted logistic regression was imple-356 mented using the *glm* function in R. As described previously (*Watson et al.*, 2021a), standard errors 357 were transformed to reflect the reduced effective sample size resulting from inclusion of sample 358 weights in the model. We considered $p < 5 \times 10^{-8}$ to be significant. 359 We used a Bayesian approach to identify a set of SNPs with 95% probability of containing the 360 causal variant at the trait-associated locus. Approximate Bayes' factors (Wakefield, 2009) were 361 calculated for each SNP in the region (a 200kb surrounding rs183868412) with a prior distribution 362 of $N(0, 0, 2^2)$. All SNPs were considered equally likely to be the causal variant a priori. A set of SNPs 363

with 95% probability of containing the causal SNP was defined as the smallest number of SNPs for 364 which the summed posterior probabilities exceed 0.95. 365

Replication samples and analysis 366

To replicate our findings from the discovery analysis we used a second sample set, recruited from 367 the same population as the discovery samples. Replication case samples were cases of bacter-368 aemia only, and did not include cases of severe malaria without culture-confirmed bacterial infec-360 tion. Case samples were recruited between 1st August 1998 and 30th October 2010. As for the 370 discovery case samples, children under 14 years with a bacterial pathogen isolated from blood on 371 admission to hospital were eligible for recruitment to the study. As above, control samples were 372 recruited as part of a birth cohort from the same population, with children recruited between the 373 ages of 3 and 12 months. Genotyping and QC procedures for these samples have been described 374 previously. In brief, study samples were genotyped using the Immunochip Consortium (Cortes 375 and Brown, 2011) array (Illumina). Sample OC was performed as for the discovery samples (above). 376 with duplicate control samples (samples common to MalariaGEN and Immunochip controls, n=78) 377 being removed from the replication set. As above, relatedness estimates and PCs were computed 378 in PLINK v1.90 (Chang et al., 2015), with the major four PCs of genotype data differentiating self-379 reported ethnicity (Figure 3-figure supplement 1). SNP OC excluded the following variants: SNP 380 missingness >1%. MAF <1% and HWE $p < 1 \times 10^{-10}$. Following OC. 143,000 genotyped variants in 381 434 cases and 1 258 control samples were taken forward for imputation. As above, imputation was performed with SHAPFIT2 (Delaneau et al., 2012) and IMPUTE2 (v2.3.2) (Howie et al., 2011, 2009) 383 with 1000 Genomes Phase III as a reference panel. 384 Following imputation, we further excluded poorly-imputed (imputation info score<0.5) and rare

385 (MAF<1%) variants and variants with HWE $p < 1 \times 10^{-10}$. At variants associated with invasive bacterial 386 disease $(p < 5 \times 10^{-8})$ in the discovery analysis, we tested for association with bacteraemia case-387 control status using logistic regression in an additive model in SNPTEST v2.5.6 (Marchini et al., 388 2007). To exclude confounding variation, we included the major four PCs of genotyping data in the 380 model. We considered evidence of association with bacteraemia in the replication samples with 300 p < 0.05 with the same direction of effect as in the discovery analysis to be significant. 301

Bayesian comparison of models of association 303

At the locus of interest, we used multinomial logistic regression, implemented in SNPTEST v2.5.6 303

(Marchini et al., 2007) to estimate the additive effect of genotype on risk of bacteraemia strati-30/

³⁹⁵ fied by pathogen, bacteraemia in the neonatal and non-neonatal periods, bacteraemia with and

without *P. falciparum* parasitaemia, and bacteraemia presenting at different time periods across a

³⁹⁷ period of declining malaria transmission intensity. For these analyses we used only samples with

³⁹⁸ culture-confirmed bacteraemia. In each case we used control status as the baseline stratum, and

³⁹⁹ included the major principal components of genotyping data to control for confounding variation

as above.

For the pathogen-stratified analysis, we defined eight case strata among the discovery cases. 401 one for each of the seven most commonly isolated organisms (Acinetobacter, n=118: β -haemolytic 402 Streptococci, n=130; E, coli, n=141; H, influenzae type b, n=113; nontyphoidal Salmonella, n=159; 403 pneumococci, n=390; S. gureus, n=152) and one stratum for the remaining other organisms (n=242). 404 For the neonatal/non-neonatal disease analysis we stratified cases as presenting in the first 28 days 405 of life (n=195) or beyond that (n=1.245). For the analysis comparing bacteraemia with and without 106 malaria we stratified cases with (n=204) and without (n=1,236) *P. falciparum* on their admission 407 blood film. For each of these analysis case strata were compared to Affymetrix-genotyped discov-408 erv control samples (n=1.895) as a baseline stratum. 400

For the analysis stratified across year of admission, we defined case strata by grouping into six 410 time periods according to their date of admission: 1998-2000 (n=498), 2001-2002 (n=349), 2003-411 2004 (n=467), 2005-2006 (n=310), 2007-2008 (n=237), 2009-2010 (n=111). For this analysis we used 412 both discovery (Affymetrix) and replication (Immunochip) case and control samples. This allowed 413 better coverage of the years later in the study, which were underrepresented in the discovery 414 samples (the discovery median admission year is 2003, c.f. 2005 for the replication samples). In 415 that analysis we used multinomial logistic regression in each cohort to estimate stratum-specific 416 effects, combining these results in a fixed effects meta-analysis using BINGWA (*Band et al., 2015*). 417 We then compared models of association using a Bayesian approach (Rautanen et al., 2016). 418 considering the following models: 419

⁴²⁰ "Null": effect size = i.e. no association with bacteraemia.

"Same": effect size $N(0, 0.2^2)$ and fixed across strata.

Additional models consider each possible combination of a fixed effect size for associated strata

and no association at other strata. For each model we calculated approximate Bayes factors (*Wake-*

field, 2009) and posterior probabilities, assuming each model to be equally likely a priori. Statistical analysis was performed in R.

426 Co-localisation analysis

We used the R package coloc v5.1.0 (*Giambartolomei et al., 2014*) to identify evidence of causal variants shared by our bacterial disease-associated locus of interest and regulatory genetic variation mapped by eOTL studies. We downloaded eOTL summary statistics describing eOTL mapping

tion mapped by eQTL studies. We downloaded eQTL summary statistics describing eQTL mapping
 in naive and stimulated monocytes (*Quach et al., 2016*), including study participants with African an-

In naive and stimulated monocytes (*Quach et al., 2016*), including study participants with African an cestry, from the eQTL catalogue (*Kerimov et al., 2021*) (https://github.com/eQTL-Catalogue/eQTL-Catalogue-restriction

accessed 28th October 2021). Coloc adopts a Bayesian approach to compare evidence for indepen-

dent or shared association signals for two traits at a given genetic locus. We used the coloc.susie()

434 command to allow co-localisation of multiple independent signals at a single locus for each trait.

435 We tested for colocalisation between invasive bacterial disease susceptibility at the BIRC6 locus

and previously-published eQTL data in naive and stimulated primary monocytes isolated from in-

dividuals of European (n=100) and African (n=100) ancestry (*Quach et al., 2016*). We considered

evidence for co-localisation for each gene and exon within a 250kb window of the peak association (rs183868412). We considered a posterior probability > 0.8 supporting a shared causal locus

439 tion (rs183868412). We considered a posterior probability > 0.8 supporting a shared causal I to be significant.

to be significant.

Acknowledgments

This publication uses genotyping data from the MalariaGEN consortial project, as described in

Malaria Genomic Epidemiology Network, et al. Nature Communications, 2019 (https://doi.org/10.1038/s414

- 019-13480-z). This study makes use of data generated by the Wellcome Trust Case Control Consor-444
- tium 2 project (Grant Reference 085475/B/08/Z). IIG and AIM are funded by National Institute for 445
- Health Research (NIHR) Clinical Lectureships. TNW and IAGS are supported by Senior Research Fel-446
- lowships from the Wellcome Trust (202800 and 098532 respectively). IAW is a Sir Henry Dale Fellow 447
- funded by the Wellcome Trust (223253/Z/21/Z), SMAART (Severe Malaria Africa A consortium for 448
- Research and Trials) is funded by a Wellcome Collaborative Award in Science grant (209265/Z/17/Z) 449
- held in part by KM and TNW. During this work AVSH was supported by a Wellcome Trust Senior 450
- Investigator Award (HCUZZ0) and by a European Research Council advanced grant (294557). The 451
- research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with 452
- additional support from the NIHR Oxford BRC. The views expressed are those of the author(s) and 463
- not necessarily those of the NHS, the NIHR or the Department of Health. This research was funded 454
- by The Wellcome Trust. A CC BY or equivalent licence is applied to the author accepted manuscript 455
- arising from this submission, in accordance with the grant's open access conditions. This paper is 456
- published with the permission of the Director of KEMRI. 457
- References 458
- Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nature 459 Reviews Immunology. 2004; 4(3):223-231. https://doi.org/10.1038/nri11308, doi: 10.1038/nri11308. 460
- Band G, Le QS, Clarke GM, Kivinen K, Hubbart C, Jeffreys AE, Rowlands K, Leffler EM, Jallow M, Conway DJ, Sisay-461
- Joof F, Sirugo G, d'Alessandro U, Toure OB, Thera MA, Konate S, Sissoko S, Mangano VD, Bougouma EC, Sirima 462
- SB, et al. Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia 463 and Oceania. Nature Communications. 2019; 10(1):5732. https://doi.org/10.1038/s41467-019-13480-z, doi: 464
- 10.1038/s41467-019-13480-z.
- 465
- Band G, Rockett KA, Spencer CCA, Kwiatkowski DP, Si Le Q, Clarke GM, Kivinen K, Leffler EM, Rockett KA, 466 Kwiatkowski DP, Spencer CCA, Rockett KA, Spencer CCA, Cornelius V, Conway DJ, Williams TN, Taylor T, 467 Kwiatkowski DP, Conway DJ, Bojang KA, et al. A novel locus of resistance to severe malaria in a region of 468
- ancient balancing selection. Nature. 2015; 526(7572):253-257. https://doi.org/10.1038/nature15390, doi: 469
- 10.1038/nature15390. 470
- Bartke T. Pohl C. Pyrowolakis G. Jentsch S. Dual Role of BRUCE as an Antiapoptotic JAP and a Chimeric E2/E3 471 Ubiguitin Ligase. Molecular Cell. 2004; 14(6):801–811. https://www.sciencedirect.com/science/article/pii/ 472
- S1097276504003041, doi: https://doi.org/10.1016/i.molcel.2004.05.018. 473
- Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, Williams T, Scott JAG, English M, Lowe BS, Peshu 474 N. Newton CRIC, Marsh K. Defining childhood severe falciparum malaria for intervention studies. PLoS Med. 475 2007 Aug: 4(8):e251. doi: 10.1371/journal.pmed.0040251. 476
- Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsa C, Slack MPE, Njenga S, Hart CA, 477 Maitland K, English M, Marsh K, Scott IAG. Bacteremia among children admitted to a rural hospital in Kenya. 478 N Engl I Med. 2005 Jan: 352(1):39-47. doi: 10.1056/NEIMoa040275. 479
- Bustamante I, Boisson-Dupuis S, Abel L, Casanova IL, Mendelian susceptibility to mycobacterial disease: ge-480 netic, immunological, and clinical features of inborn errors of IFN- immunity. Semin Immunol. 2014 Dec: 481 26(6):454-470, doi: 10.1016/j.smim.2014.09.008.
- 482
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee II. Second-generation PLINK: rising to the challenge 483 of larger and richer datasets. Gigascience. 2015; 4:7. doi: 10.1186/s13742-015-0047-8. 484
- Church J, Maitland K. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: 485 a systematic review. BMC Med. 2014 Feb; 12:31. doi: 10.1186/1741-7015-12-31. 486
- **Cortes A.** Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011 Feb: 13(1):101. doi: 487 10.1186/ar3204. 488
- Cowgill KD, Ndiritu M, Nyiro J, Slack MPE, Chiphatsi S, Ismail A, Kamau T, Mwangi I, English M, Newton CRJC, 489 Feikin DR, Scott JAG. Effectiveness of Haemophilus influenzae Type b Conjugate Vaccine Introduction Into
- 490 Routine Childhood Immunization in Kenva, IAMA, 2006 11/3/2021; 296(6):671–678, https://doi.org/10.1001/ 491
- jama.296.6.671. doi: 10.1001/jama.296.6.671. 492

- Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, Inwald D, Nadel S, Betts H, Carrol ED, de Groot
- R, Hermans PWM, Hazelzet J, Emonts M, Lim CC, Kuijpers TW, Martinon-Torres F, Salas A, Zenz W, Levin M,
- et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibil-
- ity to meningococcal disease. Nature Genetics. 2010; 42(9):772–776. https://doi.org/10.1038/ng.640, doi: 10.1038/ng.640.

Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nature Methods. 2012; 9(2):179–181. https://doi.org/10.1038/nmeth.1785. doi: 10.1038/nmeth.1785.

Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nature Reviews Immunology.
 2013; 13(10):722–737. https://doi.org/10.1038/nri3532, doi: 10.1038/nri3532.

Driscoll AJ, Deloria Knoll M, Hammitt LL, Baggett HC, Brooks WA, Feikin DR, Kotloff KL, Levine OS, Madhi SA,
 O'Brien KL, Scott JAG, Thea DM, Howie SRC, Adrian PV, Ahmed D, DeLuca AN, Ebruke BE, Gitahi C, Higdon

- MM, Kaewpan A, et al. The Effect of Antibiotic Exposure and Specimen Volume on the Detection of Bacterial
- Pathogens in Children With Pneumonia. Clinical Infectious Diseases. 2017 11/16/2021; 64(suppl_3):S368– S377. https://doi.org/10.1093/cid/cix101, doi: 10.1093/cid/cix101.
- **Ebner P**, Poetsch I, Deszcz L, Hoffmann T, Zuber J, Ikeda F. The IAP family member BRUCE regulates autophagosome-lysosome fusion. Nat Commun. 2018 Feb; 9(1):599. doi: 10.1038/s41467-018-02823-x.

Figueroa J, Andreoni J, Densen P. Complement deficiency states and meningococcal disease. Immunol Res. 1993; 12(3):295–311. doi: 10.1007/BF02918259.

Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian test for
 colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014 May;
 10(5):e1004383, doi: 10.1371/journal.pgen.1004383.

Gilchrist JJ, Rautanen A, Fairfax BP, Mills TC, Naranbhai V, Trochet H, Pirinen M, Muthumbi E, Mwarumba S,
 Njuguna P, Mturi N, Msefula CL, Gondwe EN, MacLennan JM, Chapman SJ, Molyneux ME, Knight JC, Spencer
 CCA. Williams TN. MacLennan CA, et al. Risk of nontvphoidal Salmonella bacteraemia in African children is

516 CCA, Williams TN, MacLennan CA, et al. Risk of nontyphoidal Salmonella bacteraemia in African children is
 517 modified by STAT4. Nature Communications. 2018; 9(1):1014. https://doi.org/10.1038/s41467-017-02398-z.

doi: 10.1038/s41467-017-02398-z.

Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang X, Noda T, Tsuruo T. Naito M. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function.

Nature Cell Biology. 2004; 6(9):849–860. https://doi.org/10.1038/ncb1159, doi: 10.1038/ncb1159.

Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis
 inhibitors. J Cell Biol. 1998 Jun; 141(6):1415–1422. doi: 10.1083/jcb.141.6.1415.

Hendriksen ICE, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R, Lee SJ, Tshefu AK, Woodrow C, Amos B, Karema C, Saiwaew S, Maitland K, Gomes F, Pan-Ngum W, Gesase S, Silamut K, Revburn

H, Joseph S, Chotivanich K, et al. Diagnosing severe falciparum malaria in parasitaemic African children: a

prospective evaluation of plasma PfHRP2 measurement. PLoS Med. 2012; 9(8):e1001297. doi: 10.1371/jour nal.pmed.1001297.

Hoogerwerf JJ, van Zoelen MA, Wiersinga WJ, van 't Veer C, de Vos AF, de Boer A, Schultz MJ, Hooibrink B,
 de Jonge E, van der Poll T. Gene expression profiling of apoptosis regulators in patients with sepsis. J Innate
 Immun. 2010; 2(5):461–468. doi: 10.1159/000317035.

Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg REJ, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buch-

man TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lympho-

cytes in humans. J Immunol. 2001 Jun; 166(11):6952–6963. doi: 10.4049/jimmunol.166.11.6952.

Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev
 Immunol. 2006 Nov; 6(11):813–822. doi: 10.1038/nri1943.

Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, Cobb JP, Coopersmith C, Karl IE.
 Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol. 2002 Mar; 168(5):2493–2500. doi: 10.4049/ijmmunol.168.5.2493.

Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011 Nov;
 1(6):457–470. doi: 10.1534/g3.111.001198.

- Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009 Jun; 5(6):e1000529. doi: 10.1371/jour-
- 544 nal.pgen.1000529.
- Jia R, Bonifacino JS. Negative regulation of autophagy by UBA6-BIRC6-mediated ubiquitination of LC3. Elife. 2019 Nov; 8. doi: 10.7554/eLife.50034.
- 547 Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, Samoviča M, Sakthivel MP, Kuzmin I, Tre-
- vanion SJ, Burdett T, Jupp S, Parkinson H, Papatheodorou I, Yates AD, Zerbino DR, Alasoo K. A compendium
- of uniformly processed human gene expression and splicing quantitative trait loci. Nature Genetics. 2021;
- 550 53(9):1290–1299. https://doi.org/10.1038/s41588-021-00924-w, doi: 10.1038/s41588-021-00924-w.
- Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drénou B.
 Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock. 2002
 Dec: 18(6):487-494. doi: 10.1097/00024382-200212000-00001.
- Lo S, Yuan SSF, Hsu C, Cheng YJ, Chang YF, Hsueh HW, Lee PH, Hsieh YC. Lc3 Over-Expression Improves Survival
 and Attenuates Lung Injury Through Increasing Autophagosomal Clearance in Septic Mice. Annals of Surgery.
- 556 2013; 257(2). https://journals.lww.com/annalsofsurgery/Fulltext/2013/02000/Lc3_Over_Expression_Improves_
- 557 Survival_and.26.aspx.
- Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association
 studies by imputation of genotypes. Nature Genetics. 2007; 39(7):906–913. https://doi.org/10.1038/ng2088.
- studies by imputation of doi: 10.1038/ng2088.
- Ndila CM, Uyoga S, Macharia AW, Nyutu G, Peshu N, Ojal J, Shebe M, Awuondo KO, Mturi N, Tsofa B, Sepúlveda
- N, Clark TG, Band G, Clarke G, Rowlands K, Hubbart C, Jeffreys A, Kariuki S, Marsh K, Mackinnon M, et al.
- Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control
- association study. Lancet Haematol. 2018 Aug; 5(8):e333–e345. doi: 10.1016/S2352-3026(18)30107-8.
- Picard C, von Bernuth H, Ku CL, Yang K, Puel A, Casanova JL. Inherited human IRAK-4 deficiency: an update.
 Immunol Res. 2007; 38(1-3):347–352. doi: 10.1007/s12026-007-0006-2.
- **Quach H**, Rotival M, Pothlichet J, Loh YHE, Dannemann M, Zidane N, Laval G, Patin E, Harmant C, Lopez M,
- Deschamps M, Naffakh N, Duffy D, Coen A, Leroux-Roels G, Clément F, Boland A, Deleuze JF, Kelso J, Albert
- 569 ML, et al. Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations.
- ⁵⁷⁰ Cell. 2016 Oct; 167(3):643–656. doi: 10.1016/j.cell.2016.09.024.
- 571 Rautanen A, Pirinen M, Mills TC, Rockett KA, Strange A, Ndungu AW, Naranbhai V, Gilchrist JJ, Bellenguez C,
- 572 Freeman C, Band G, Bumpstead SJ, Edkins S, Giannoulatou E, Gray E, Dronov S, Hunt SE, Langford C, Pearson
- RD, Su Z, et al. Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in
- 574 Kenyan Children. Am J Hum Genet. 2016 Jun; 98(6):1092–1100. doi: 10.1016/j.ajhg.2016.03.025.
- Scott JAG, Berkley JA, Mwangi I, Ochola L, Uyoga S, Macharia A, Ndila C, Lowe BS, Mwarumba S, Bauni E, Marsh K,
 Williams TN. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based,
 case-control study and a longitudinal study. Lancet. 2011 Oct; 378(9799):1316–1323. doi: 10.1016/S0140 6736(11)60888-X.
- Silaba M, Ooko M, Bottomley C, Sande J, Benamore R, Park K, Ignas J, Maitland K, Mturi N, Makumi A, Otiende M, Kagwanja S, Safari S, Ochola V, Bwanaali T, Bauni E, Gleeson F, Deloria Knoll M, Adetifa I, Marsh K, et al. Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. The Lancet Global Health. 2019 2021/11/03; 7(3):e337–e346. https://doi.org/10.1016/S2214-109X(18)30491-1, doi: 10.1016/S2214-109X(18)30491-1.
- Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other
 BIRPs. Genome Biology. 2001; 2(7):reviews3009.1. https://doi.org/10.1186/gb-2001-2-7-reviews3009, doi: 10.1186/gb-2001-2-7-reviews3009.
- Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah
 F, Abdelalim A, Abdollahi M, Abdollahpour I, Abolhassani H, Aboyans V, Abrams EM, Abreu LG, Abrigo MRM,
- Abu-Raddad LJ, Abushouk AI, Acebedo A, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
- The Lancet. 2020 2021/11/03; 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9, doi:
- **593** 10.1016/S0140-6736(20)30925-9.

- Wakefield J. Bayes factors for genome-wide association studies: comparison with P-values. Genet Epidemiol.
 2009 Jan; 33(1):79–86. doi: 10.1002/gepi.20359.
- Watson JA, Ndila CM, Uyoga S, Macharia A, Nyutu G, Mohammed S, Ngetsa C, Mturi N, Peshu N, Tsofa B, Rockett
- 507 K, Leopold S, Kingston H, George EC, Maitland K, Day NP, Dondorp AM, Bejon P, Williams T, Holmes CC, 608 et al. Improving statistical power in severe malaria genetic association studies by augmenting phenotypic
- precision. Elife. 2021 Iul: 10. doi: 10.7554/eLife.69698.
- 600 Watson JA, Uyoga S, Wanjiku P, Makale J, Nyutu GM, Mturi N, George EC, Woodrow CJ, Day NP, Bejon P, Opoka
- RO, Dondorp AM, John CC, Maitland K, Williams TN, White NJ. Improving the diagnosis of severe malaria
- in African children using platelet counts and plasma Pf HRP2 concentrations. medRxiv. 2021; https://www.
- medrxiv.org/content/early/2021/10/30/2021.10.27.21265557, doi: 10.1101/2021.10.27.21265557.
- 604 Williams TN, Uyoga S, Macharia A, Ndila C, McAuley CF, Opi DH, Mwarumba S, Makani J, Komba A, Ndiritu
- MN, Sharif SK, Marsh K, Berkley JA, Scott JAG. Bacteraemia in Kenyan children with sickle-cell anaemia: a
- retrospective cohort and case-control study. Lancet. 2009 Oct; 374(9698):1364–1370. doi: 10.1016/S0140-
- 607 6736(09)61374-Х.











Figure 2-Figure supplement 2. Principal components of genome-wide genotyping data in discovery samples. Individuals are color-coded according to genotyping platform; Affymetrix SNP 6.0 in purple, Illumina Omni 2.5M in orange.



Figure 2-Figure supplement 3. Principal components of genome-wide genotyping data in discovery samples. Individuals are color-coded according to self-reported ethnicity; Chonyi in red, Giriama in blue, Kauma in green and other in grey.



Figure 2-Figure supplement 4. Quantile-quantile plot of invasive bacterial infection in Kenyan children. QQ plot of weighted logistic regression GWAS of invasive bacterial disease in Kenyan children (2,588 cases, 2,812 controls).



Figure 3-Figure supplement 1. Principal components of genome-wide genotyping data in replication samples. Individuals are color-coded according to self-reported ethnicity; Chonyi in red, Giriama in blue, Kauma in green and other in grey.